<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03093051</url>
  </required_header>
  <id_info>
    <org_study_id>CL005</org_study_id>
    <secondary_id>2R44HL107055-02</secondary_id>
    <nct_id>NCT03093051</nct_id>
  </id_info>
  <brief_title>Unpinning Termination Therapy for VT (US)</brief_title>
  <official_title>A Clinical Feasibility Study to Evaluate the Safety and Performance of Low-Energy Unpinning Termination Therapy in Patients With VT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardialen, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cardialen, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observation study evaluates the safety and performance of UPT therapy in subjects during&#xD;
      either an indicated ventricular tachycardia ablation procedure or an ICD implant procedure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This non-blinded, single-arm open-label, phase 1 pilot, acute research feasibility trial aims&#xD;
      to demonstrate that the safety and effectiveness of Unpinning Termination (UPT)&#xD;
      electrotherapy observed in the canine can be translated to humans and to demonstrate the&#xD;
      safety and performance of UPT electrotherapy in the human population most likely to benefit&#xD;
      from this therapy. This study evaluates the safety and performance of UPT therapy in subjects&#xD;
      during either an indicated ventricular tachycardia (VT) catheter ablation or an indicated&#xD;
      initial implant or device replacement of an implantable cardioverter defibrillator (ICD).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 8, 2019</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients undergoing a routine clinically indicated procedure will have the investigational therapy delivered during the clinically indicated procedure.</intervention_model_description>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arrhythmia Termination as assessed by the number of episodes restored to sinus rhythm</measure>
    <time_frame>During study procedure</time_frame>
    <description>Assess the safety and performance of the Cardialen External Stimulation System and safety and performance ofUPT therapy</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Ventricular Tachycardia</condition>
  <arm_group>
    <arm_group_label>UPT Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational therapy (UPT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Unpinning Termination therapy</intervention_name>
    <description>Electrotherapy comprised of standard biphasic and monophasic pacing pulses</description>
    <arm_group_label>UPT Treatment</arm_group_label>
    <other_name>Multi-Stage Therapy</other_name>
    <other_name>Multi-Stage Electrotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        The subject must meet all of the following inclusion criteria:&#xD;
&#xD;
          1. Life expectancy of 1 year or greater&#xD;
&#xD;
          2. Male or female between 18 and 80 years of age&#xD;
&#xD;
          3. Willing and able to comply with the study protocol, provide a written informed consent&#xD;
&#xD;
          4. Indication for an endocardial VT catheter ablation for symptomatic VT with use of CESS&#xD;
             V1.0 or CESS V1.1 OR an indication for an ICD procedure (de novo implant, replacement&#xD;
             or upgrade) or de novo CRTD procedure for the risk of or presence of VT (CESS 1.0 and&#xD;
             1.1)&#xD;
&#xD;
          5. Etiology of arrhythmia, or risk of arrhythmia being ischemic cardiomyopathy or&#xD;
             non-ischemic cardiomyopathy&#xD;
&#xD;
          6. Medically stable at time of consent to undergo DFT testing performed under general&#xD;
             anesthesia or conscious sedation as determined by the investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The subject must not meet any of the following exclusion criteria:&#xD;
&#xD;
          1. Medically unstable at time of study and unsafe to undergo DFT testing under general&#xD;
             anesthesia or conscious sedation as determined by the investigator&#xD;
&#xD;
          2. Hemodynamic instability as determined by the investigator&#xD;
&#xD;
          3. AF or atrial flutter at time of Study Procedure and no anticoagulation for preceding 3&#xD;
             weeks and no preoperative transesophageal echocardiographic, Cardiac CT or&#xD;
             Intracardiac echocardiographic confirmation of the absence of LA thrombus&#xD;
&#xD;
          4. Presence of intracardiac thrombus&#xD;
&#xD;
          5. Inability to pass catheters to heart due to vascular limitations&#xD;
&#xD;
          6. Cardiovascular anatomical defects that would complicate placement of the lead or&#xD;
             catheter required by the protocol, including congenital heart disease and cardiac vein&#xD;
             anomalies as determined by the investigator&#xD;
&#xD;
          7. Pregnancy confirmed by test within 7 days of procedure&#xD;
&#xD;
          8. Presence of a chronically implanted lead in the CS&#xD;
&#xD;
          9. Presence of a ventricular assist device, including intra-aortic balloon pump&#xD;
&#xD;
         10. Subjects indicated for VT ablation and experiencing VF&#xD;
&#xD;
         11. Subjects requiring the use of inotropes and/or vasopressors for hemodynamic support&#xD;
             within the 3 days prior to the study&#xD;
&#xD;
         12. Prior VT catheter ablation with associated hemodynamic compromise despite pressor&#xD;
             agents or stroke&#xD;
&#xD;
         13. Incessant VT/VF or VT/VF storm within six months of scheduled procedure&#xD;
&#xD;
         14. LVEF &lt; 20%&#xD;
&#xD;
         15. New York Heart Association (NYHA) Class IV heart failure&#xD;
&#xD;
         16. Planned epicardial VT ablation on the same day as the research study&#xD;
&#xD;
         17. History of hyper-coagulable state that could increase risk of thromboembolic events&#xD;
&#xD;
         18. History of hemodynamic compromise due to valvular heart disease requiring IV inotropes&#xD;
             or other circulatory support&#xD;
&#xD;
         19. Unstable coronary artery disease as determined by the investigator&#xD;
&#xD;
         20. Severe proximal three-vessel or left main coronary artery disease, without&#xD;
             revascularization as determined by the investigators&#xD;
&#xD;
         21. History of embolic stroke, Transient Ischemic Attack or other thromboembolic event in&#xD;
             the past 6 months&#xD;
&#xD;
         22. History of Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Dysplasia,&#xD;
             Congenital Heart Anomaly, Cardiac Amyloidosis, Genetic Cardiac Channelopathy or&#xD;
             Cardiac Sarcoidosis&#xD;
&#xD;
         23. Cardiovascular surgery or intervention within 1 month prior to enrollment or planned&#xD;
             for up to 1 month after enrollment (other than the planned treatment procedure)&#xD;
&#xD;
         24. Morbid obesity: BMI&gt;39 kg/m2&#xD;
&#xD;
         25. Cognitive or mental health status that would interfere with study participation and&#xD;
             proper informed consent&#xD;
&#xD;
         26. Presence of mechanical tricuspid valve&#xD;
&#xD;
         27. Active Endocarditis&#xD;
&#xD;
         28. Ventricular arrhythmia with etiology of sarcoid flare&#xD;
&#xD;
         29. Previously implanted lead is under recall by manufacturer or evidence of lead failure&#xD;
             as determined by the investigator&#xD;
&#xD;
         30. End Stage Renal Disease on hemodialysis or peritoneal dialysis, or creatinine&#xD;
             clearance &lt;15 ml/min&#xD;
&#xD;
         31. Any other medical condition which may affect the outcome of this study or safety of&#xD;
             the subject as determined by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel H. Cooper, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dave Munneke, MS</last_name>
    <phone>612-804-9516</phone>
    <email>DMunneke@cardialen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tom Rasmussen, BA</last_name>
    <phone>719-659-6363</phone>
    <email>TRasmussen@cardialen.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mills Peninsula Medical Center</name>
      <address>
        <city>Burlingame</city>
        <state>California</state>
        <zip>94010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milena Ferreira</last_name>
      <email>ferreiml@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Christopher Woods, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Group</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelley Allen</last_name>
      <phone>916-453-2626</phone>
      <email>Shelley.allen@dignityhealth.org</email>
    </contact>
    <investigator>
      <last_name>P. Gearoid O'Neill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MercyOne Des Moines Medical Center</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Young, RN</last_name>
      <phone>515-633-3600</phone>
    </contact>
    <investigator>
      <last_name>Jason D. Meyers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minneapolis VA Healthcare System</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Morgan</last_name>
      <phone>612-467-2455</phone>
      <email>Jill.morgan@va.gov</email>
    </contact>
    <investigator>
      <last_name>Venkatakrishna N Tholakanahalli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janice Amsler</last_name>
      <phone>314-747-8542</phone>
      <email>jmamsler@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel H Cooper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashleigh Keiter</last_name>
      <email>Ashleigh.keiter@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>John D Hummel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OhioHealth Riverside Methodist Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audrey McDonald</last_name>
      <email>Audrey.McDonald@ohiohealth.com</email>
    </contact>
    <investigator>
      <last_name>Anish Amin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Janardhan AH, Gutbrod SR, Li W, Lang D, Schuessler RB, Efimov IR. Multistage electrotherapy delivered through chronically-implanted leads terminates atrial fibrillation with lower energy than a single biphasic shock. J Am Coll Cardiol. 2014 Jan 7-14;63(1):40-8. doi: 10.1016/j.jacc.2013.07.098. Epub 2013 Sep 26.</citation>
    <PMID>24076284</PMID>
  </reference>
  <reference>
    <citation>Janardhan AH, Li W, Fedorov VV, Yeung M, Wallendorf MJ, Schuessler RB, Efimov IR. A novel low-energy electrotherapy that terminates ventricular tachycardia with lower energy than a biphasic shock when antitachycardia pacing fails. J Am Coll Cardiol. 2012 Dec 11;60(23):2393-8. doi: 10.1016/j.jacc.2012.08.1001. Epub 2012 Nov 7.</citation>
    <PMID>23141483</PMID>
  </reference>
  <reference>
    <citation>Li W, Janardhan AH, Fedorov VV, Sha Q, Schuessler RB, Efimov IR. Low-energy multistage atrial defibrillation therapy terminates atrial fibrillation with less energy than a single shock. Circ Arrhythm Electrophysiol. 2011 Dec;4(6):917-25. doi: 10.1161/CIRCEP.111.965830. Epub 2011 Oct 6.</citation>
    <PMID>21980076</PMID>
  </reference>
  <reference>
    <citation>Efimov I, Ripplinger CM. Virtual electrode hypothesis of defibrillation. Heart Rhythm. 2006 Sep;3(9):1100-2. Epub 2006 Mar 10.</citation>
    <PMID>16945810</PMID>
  </reference>
  <reference>
    <citation>Ripplinger CM, Krinsky VI, Nikolski VP, Efimov IR. Mechanisms of unpinning and termination of ventricular tachycardia. Am J Physiol Heart Circ Physiol. 2006 Jul;291(1):H184-92. Epub 2006 Feb 24.</citation>
    <PMID>16501014</PMID>
  </reference>
  <reference>
    <citation>Li W, Ripplinger CM, Lou Q, Efimov IR. Multiple monophasic shocks improve electrotherapy of ventricular tachycardia in a rabbit model of chronic infarction. Heart Rhythm. 2009 Jul;6(7):1020-7. doi: 10.1016/j.hrthm.2009.03.015. Epub 2009 Mar 11.</citation>
    <PMID>19560090</PMID>
  </reference>
  <reference>
    <citation>Ambrosi CM, Ripplinger CM, Efimov IR, Fedorov VV. Termination of sustained atrial flutter and fibrillation using low-voltage multiple-shock therapy. Heart Rhythm. 2011 Jan;8(1):101-8. doi: 10.1016/j.hrthm.2010.10.018. Epub 2010 Oct 19.</citation>
    <PMID>20969974</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 13, 2017</study_first_submitted>
  <study_first_submitted_qc>March 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2017</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Termination</keyword>
  <keyword>Unpinning</keyword>
  <keyword>Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

